This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Real validated WNT2 Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-WNT2 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
| Expected band | ~40.4 kDa | |
| Gel | 12–15% (standard starting point) | |
| Negative control | Suggested KO / knockdown lysate |
| PTM | Glycosylated + Cleaved | |
| Caveat | Modification-state controls | |
| Gene-set association | MSigDB Hallmark membership | |
| Isoform | 1 isoform(s) |
The M03226 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | (1) Jurkat cell lysate; (2) SKBR-3 cell lysate (catalog M03226) |
| Gel % | 12–15% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Standard semi-dry transfer; verify efficiency (standard starting point) |
| Membrane | 0.45 µm PVDF (standard starting point) |
| Blocking | 5% milk or 5% BSA in TBST (standard starting point) |
| Primary antibody | M03226; use the WB datasheet starting dilution (standard starting point) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | Species-matched HRP conjugate at validated dilution (standard starting point) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
Full-length WNT2 is predicted at 40.4 kDa; signal-peptide cleavage and Asn295 glycosylation could affect migration, but no empirical band size is supplied.
| Band near 40.4 kDa | Consistent with the predicted full-length WNT2 mass; identity needs confirmation |
| Band below 40.4 kDa | Could reflect removal of the 1..25 signal peptide |
| Band above 40.4 kDa | N-linked glycosylation at Asn295 is a possible contributor, but a shift is unproven |
| Little or no band in whole-cell lysate | WNT2 is secreted into the extracellular space and matrix |
| UniProt full-length predicted mass | Provides a 40.4 kDa reference, not a measured band position |
| Signal peptide at residues 1..25 | Contributes to precursor mass before processing |
| Signal-peptide cleavage | Produces a smaller mature chain than the precursor; migration is not supplied |
| N-linked glycosylation at Asn295 | May alter apparent size; the magnitude of any shift is unknown |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | WNT2 is secreted and extracellular | Check conditioned medium or an extracellular fraction alongside a positive control |
| Band higher than expected | Asn295 glycosylation is a possible contributor, but the cause is unconfirmed | Compare treated and untreated samples with a band-identity control |
| Band lower than expected | Removal of the 1..25 signal peptide is possible | Confirm identity with an independent antibody or WNT2 depletion |
| Broad smear instead of sharp band | The supplied features do not establish a cause; variable Asn295 glycosylation is possible | Compare glycosidase-treated and untreated samples and confirm WNT2 identity |
| Multiple bands | Processing or Asn295 glycosylation could contribute, but distinct bands are not established | Use WNT2 depletion and compare treated with untreated samples |
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No high/medium HPA tissues identified in the supplied evidence. | ||||
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No lower-expression tissue rows available in the supplied evidence. | ||||
Deeper troubleshooting and optimisation questions for WNT2, answered from its protein features.
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Two the supplier anti-WNT2 antibodies have Western blot images. M03226 is shown with Jurkat and SKBR-3 cell lysates; PB9461 is shown with COLO320, MCF-7, and HeLa whole-cell lysates, with a reported band near 40 kDa. No publication evidence is supplied.
Which to pick: Choose M03226 for its listed human, mouse, and rat reactivity, or PB9461 for listed human reactivity and a detailed Western blot protocol. Both have blot images; the captions document the named cell lysates, not testing across every listed species.